The prestigious New England Journal of Medicine has published a groundbreaking article, led by Professor Messoud Ashina, on a potential new treatment for migraine. The study focuses on a drug that inhibits the signaling of PACAP (pituitary adenylate cyclase-activating polypeptide), a molecule implicated in triggering migraine attacks.
In 2009, Professor Ashina’s lab was the first to identify PACAP as a trigger for migraine, proposing it as a potential drug target. Fifteen years later, the research has culminated in a landmark paper demonstrating the efficacy of this approach.
Professor Messoud Ashina is a highly esteemed Danish-Azerbaijani neurologist and one of the foremost experts in migraine and headache disorders worldwide. He currently holds the position of Professor of Neurology at the University of Copenhagen and serves as a Senior Consultant in Neurology at Copenhagen University Hospital. In these roles, he leads innovative research and clinical efforts to advance the understanding and treatment of migraine.
With decades of experience, Professor Ashina is recognized for his profound expertise in medical research. He earned his medical degree in 1988 from Azerbaijan Medical University before furthering his education in Denmark, where he obtained both his PhD and Doctor of Medical Science (D.M.Sc.) degrees from the University of Copenhagen. His research, particularly on the mechanisms and treatment of migraine, has made a significant global impact.
Professor Ashina’s distinguished career is marked by numerous accolades, including the prestigious TÜBA Academy Prize from the Turkish Academy of Sciences and the KFJ Prize from the University of Copenhagen.
